Back to top
more

AxoGen, Inc. (AXGN)

(Delayed Data from NSDQ)

$21.61 USD

21.61
285,789

-0.89 (-0.89%)

Updated Mar 3, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (184 out of 254)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AxoGen (AXGN) Q1 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

What's in Store for Humana (HUM) Stock in Q4 Earnings?

Higher enrollment and strong segmental results are expected to help Humana (HUM) in fourth-quarter earnings.

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AxoGen (AXGN) Q3 Earnings Preview: What's in the Cards?

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1

Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.

Sweta Killa headshot

Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Sweta Killa headshot

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

Style Box ETF report for DWAS

AxoGen (AXGN) Enters Overbought Territory

AxoGen, Inc. (AXGN) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Mylan (MYL) Surges: Stock Moves 16.2% Higher

Mylan N.V. (MYL) was a big mover last session, as the company saw its shares rise more than 16% on the day amid huge volumes.

AxoGen (AXGN) Shows Strength: Stock Adds 6.1% in Session

AxoGen, Inc. (AXGN) shares rose a little above 6% in the last trading session.

Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp

Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp